Investigating how CD14 and TRIF affect immune responses in sepsis and acute respiratory distress syndrome.
Official title: CD14 collaborates with TRIF to mediate septic responses downstream of TNF receptors
Funded at Tufts University Boston · NIH-10986131 · Data updated 2026-11-12
This study is looking at how a protein called CD14 affects severe inflammation in serious conditions like sepsis and ARDS, with the hope of finding new ways to help patients who are dealing with these tough health challenges.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | November 14, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $240,075 |
| NIH project number | 5R21AI176055-02 |
| Project ID | NIH-10986131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults experiencing severe bacterial infections or acute respiratory distress syndrome.
✕Less likely to help
Patients with mild infections or those not experiencing respiratory distress may not benefit from this research.
What this research studies
This research explores the role of CD14, a coreceptor involved in the immune response, in mediating severe inflammatory reactions during conditions like sepsis and acute respiratory distress syndrome (ARDS). By examining how CD14 interacts with other proteins like TRIF and TNFα, the study aims to understand the mechanisms behind excessive inflammation and immune paralysis. The approach includes both laboratory experiments and biochemical analyses to uncover potential therapeutic targets for managing these critical conditions. Patients with severe infections or ARDS may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage inflammation and improve outcomes for patients suffering from sepsis and ARDS.
How similar studies have gone: Previous research has shown promising results in targeting inflammatory pathways similar to those being investigated in this study, indicating potential for success.
Where this research is happening
-
Tufts University Boston
Boston, United States Active
Researchers
- Principal investigator: Bunnell, Stephen C — Tufts University Boston
- Study coordinator: Bunnell, Stephen C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.